Wikipedia -WSS

Wikipedia

author：leisure time 2025-10-01 00:47:48 - browse：85

Metastatic Melanoma Cells – cancer research coverage from STAT — Metastatic melanoma cells NCI/NIH

Cancer drugs can burn through tumors like a wildfire, killing off the vast majority of malignant cells. But a few stubborn cells often end up surviving, seeding a recurrence of the disease. The prevailing theory behind this drug resistance is built on natural selection: Among the vast and genetically diverse population of cancer cells in a tumor, some have random mutations that help these cells survive an onslaught.

“But this is not the full picture,” said Yogesh Goyal, a cancer researcher at Northwestern University. Goyal and his colleagues at the University of Pennsylvania demonstrated in a series of experiments that cancer cells can survive treatments just by having certain genes turned on, even if they were nearly genetically identical to cancer cells that died but had activated different genes.

“We think this work stands to really change how we think about therapy resistance,” said Arjun Raj, the study’s co-senior author and a bioengineer at the University of Pennsylvania.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Activists slam private health insurers over coverage restrictions
Next article： A virus, fished out of a lake, may have saved a man’s life

WSS

Analysis of telehealth claims data suggest service duplication

Biotech lab space demand falls sharply

EpiPen alternative approval delay highlights citizen petition issue

Colorectal cancer study finds potential in overlooked immune cell

Eli Lilly buys Point Biopharma in radiopharmaceuticals play

How Vertex's cystic fibrosis drug is changing patients' lives

knowledge

Wikipedia

explore

BioMarin wins approval for gene therapy to treat hemophilia A

Microbiome research is starting to find links to chronic diseases

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

Eli Lilly buys Point Biopharma in radiopharmaceuticals play

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

What to expect at HLTH 2023, the health care industry conference

Medicare details structure of new drug price negotiation program

Histogen: Failed biotech offers rare public look inside

Psychedelics group wrestles with new pharma identity

In $4.8 billion deal, Bristol Myers Squibb to buy cancer player Mirati

hotspot

Intarcia’s device

Liquid biopsy for lung cancer is launched by Delfi

Was Amgen transparent enough on FDA's concern on cancer drug?

Phenylephrine and the overlooked value of the placebo effect

Liquid biopsy for lung cancer is launched by Delfi

A virus, fished out of a lake, may have saved a man’s life

Wikipedia

knowledge

leisure time

focus